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Grainyhead-like 2 inhibits the coactivator 
p300, suppressing tubulogenesis and the 
epithelial–mesenchymal transition
ABSTRACT Developmental morphogenesis and tumor progression require a transient or 
stable breakdown of epithelial junctional complexes to permit programmed migration, inva-
sion, and anoikis resistance, characteristics endowed by the epithelial–mesenchymal transi-
tion (EMT). The epithelial master-regulatory transcription factor Grainyhead-like 2 (GRHL2) 
suppresses and reverses EMT, causing a mesenchymal–epithelial transition to the default 
epithelial phenotype. Here we investigated the role of GRHL2 in tubulogenesis of Madin–
Darby canine kidney cells, a process requiring transient, partial EMT. GRHL2 was required for 
cystogenesis, but it suppressed tubulogenesis in response to hepatocyte growth factor. Sur-
prisingly, GRHL2 suppressed this process by inhibiting the histone acetyltransferase coactiva-
tor p300, preventing the induction of matrix metalloproteases and other p300-dependent 
genes required for tubulogenesis. A 13–amino acid region of GRHL2 was necessary for inhibi-
tion of p300, suppression of tubulogenesis, and interference with EMT. The results demon-
strate that p300 is required for partial or complete EMT occurring in tubulogenesis or tumor 
progression and that GRHL2 suppresses EMT in both contexts through inhibition of p300.
INTRODUCTION
The protein p300 is a coactivator of transcription that interacts with 
at least 400 DNA factors to activate transcription from thousands of 
enhancers/promoters, mostly contingent upon its intrinsic histone 
acetyltransferase (HAT) activity. In this context, it is viewed as an 
“integrator” factor that serves as a nexus among multiple signaling 
pathways and programs of gene expression (Kamei et al., 1996; Vo 
and Goodman, 2001; Bedford et al., 2010; Yao et al., 2013). Accord-
ingly, p300/CREB-binding protein (CBP)–null mice die at embryonic 
days 9.5–11.5 with massive deficits of mesenchymal cells and ery-
throid cells, as well as with defects in neurulation and heart develop-
ment (Oike et al., 1999; Yao et al., 2013). p300 is essential for the 
differentiation of muscle, erythroid lineages, osteoblast, oligoden-
drocytes, and stem cells (Puri et al., 1997; Oike et al., 1999; Blobel, 
2000; Polesskaya et al., 2001; Narayanan et al., 2004; Teo and Kahn, 
2010; Zhang et al., 2016). A recent study showed that p300 is a 
marker for superenhancers, positioning it to control cell state transi-
tions (Witte et al., 2015).
Grainyhead-like 2 (GRHL2) is one of the three genes comprising 
a family of mammalian transcription factors related to Drosophila 
Grainyhead, the first zygotically encoded transcription factor ex-
pressed during the maternal-to-zygotic transition (Harrison et al., 
2010). GRHL2 is important for epithelial barrier assembly in, for ex-
ample, the morphogenesis of kidney collecting ducts, placenta, lung 
alveoli, and the mammary gland ductal system (through OVOL2, a 
GRHL2 target gene) (Gao et al., 2013; Watanabe et al., 2014; 
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E-cadherin expression showed that EMT did not occur in response 
to the knockdown of GRHL2 alone (Figure 1C and Supplemental 
Figure S1 Video). GRHL2 had only modest effects on the phosphor-
ylation status of two established HGF/Met signaling mediators, Erk 
and Akt (Supplemental Figure S2).
We then examined the effects of GRHL2 on HGF-induced tubu-
logenesis in the three-dimensional collagen model. GRHL2 expres-
sion caused the formation of larger cysts than in vector control cells, 
consistent with previous reports on hepatic bile duct cells (Figure 1D; 
Tanimizu and Mitaka, 2013). GRHL2 significantly suppressed tubulo-
genesis/branching morphogenesis after HGF treatment (Figure 1D); 
a similar effect of murine Grhl2 was observed in mouse inner medul-
lary collecting-duct cell line (Supplemental Figure S3A), indicating 
the important role of GRHL2 down-regulation in tubulogenesis. Con-
versely, the stable knockdown of GRHL2 prevented cystogenesis 
(Supplemental Figure S3B), presumably by down-regulating epithe-
lial adhesion molecules (Werth et al., 2010; Senga et al., 2012). Tran-
sient knockdown of GRHL2 after cyst formation using a doxycycline-
induced shRNA vector, however, clearly indicated that the loss of 
GRHL2 promoted tubulogenesis (Supplemental Figure S4A). There 
was no effect of the GRHL2 shRNA on cell proliferation (Supplemen-
tal Figure S4B). These results indicated that GRHL2 suppressed 
HGF-activated cell scattering and tubulogenesis.
GRHL2 suppresses the expression of matrix 
metalloproteases
To identify GRHL2 target genes responsible for the attenuation 
of cellular responses to HGF/Met signaling, we used RNA-se-
quencing (RNA-Seq) to compare MDCK cells with constitutive 
GRHL2 expression versus GRHL2 depletion with either no treat-
ment or HGF induction (24 h). This experimental scheme allowed 
for two distinct comparisons: genes regulated by HGF in the ab-
sence versus presence of GRHL2, and genes regulated by GRHL2 
with versus without HGF induction. GRHL2 down-regulated 
several known matrix metalloprotease (MMP) family members 
(Table 1; confirmed by quantitative PCR [qPCR] in Figure 2A). In 
light of the established importance of specific MMPs for tubulo-
genesis in the MDCK and mIMCD-3 cell culture models (Hotary 
et al., 2000; Jorda et al., 2005; Hellman et al., 2008; Chacon-
Heszele et al., 2014), we verified their importance for branching 
tubulogenesis in embryonic kidneys cultured ex vivo using the 
generalized MMP inhibitor batimastat (Supplemental Figure S5). 
The down-regulation of MMPs by GRHL2 contributed signifi-
cantly to the tubulogenesis-suppressing effect of constitutive 
GRHL2 expression, although additional contributions from EMT/
mesenchymal-epithelial transition (MET)–related GRHL2 genes 
are likely.
To investigate the transcriptional mechanisms of MMP gene 
regulation by GRHL2, we assayed MMP1 and MMP14 promoters 
as luciferase reporter constructs by cotransfection in HT1080 
fibrosarcoma cells, in which the endogenous MMPs are ex-
pressed constitutively (Tang and Hemler, 2004; Nonaka et al., 
2005). GRHL2 was found to suppress MMP1 and MMP14 pro-
moters using adenovirus E1a protein, a known repressor of MMP 
genes, as a positive control (Figure 2B). These results demon-
strated that GRHL2 repressed MMP1 and MMP14 promoters; 
however, examination of the promoter sequences used in our 
reporter constructs did not indicate the presence of GRHL2 
DNA–binding consensus sites (Wilanowski et al., 2002; Gao 
et al., 2013; Aue et al., 2015; Walentin et al., 2015), suggesting 
a subtler mechanism for repression not involving direct DNA 
binding.
Aue et al., 2015; Walentin et al., 2015). Grainyhead-like factors are 
also critical for diverse developmental events that involve the forma-
tion of epithelial barriers, including epidermal assembly, neural crest 
formation, and, in the adult, wound healing (Wilanowski et al., 2002; 
Gustavsson et al., 2008; Wang and Samakovlis, 2012; Mlacki et al., 
2015). GRHL2 activates the expression of multiple genes encoding 
epithelial cell adhesion molecules (e.g., E-cadherin, desmosomal 
proteins, tight junction proteins) and, due to its widespread expres-
sion, may be generally important for enforcing an epithelial pheno-
type (Wilanowski et al., 2002; Ting et al., 2003, 2005; Auden et al., 
2006; Rifat et al., 2010; Werth et al., 2010; Boglev et al., 2011; Cieply 
et al., 2012; Senga et al., 2012; Tanimizu and Mitaka, 2013; Aue 
et al., 2015). Correspondingly, GRHL2 expression plays an important 
role in suppressing the oncogenic EMT, thereby functioning as a tu-
mor suppressor that enhances anoikis sensitivity (Cieply et al., 2012, 
2013; Mlacki et al., 2015); in fact, the gene most tightly correlated 
with E-cadherin expression is GRHL2 (Kohn et al., 2014).
The opposing roles of GRHL2 in establishing the epithelial state 
versus p300 in differentiation—including EMT—motivated us to in-
vestigate a potential role for GRHL2 in inhibiting p300 function. Kid-
ney tubulogenesis is contingent upon temporal and spatial regula-
tion of epithelial cells, in which GRHL2, which is expressed in the 
ureteric buds of the developing kidney, plays a critical organizing 
role (Schmidt-Ott et al., 2005; Aue et al., 2015; Walentin et al., 
2015). Madin–Darby canine kidney (MDCK) tubulogenesis in re-
sponse to hepatocyte growth factor (HGF) models some aspects of 
kidney collecting-duct tubulogenesis in vivo and requires a tran-
sient, partial EMT (Pollack et al., 1998, 2004; O’Brien et al., 2002; 
Leroy and Mostov, 2007; Hellman et al., 2008; Jung et al., 2012; 
Zhang et al., 2014). HGF causes MDCK cells to undergo cell scatter-
ing in two-dimensional culture and induces tubulogenesis of MDCK 
cysts that form in a three-dimensional collagen gel (Wang et al., 
1990; Pollack et al., 2004). Induction of MMP1 and MMP13 by HGF 
through AP1/p300 complexes is required for tubulogenesis in the 
MDCK model (Benbow and Brinckerhoff, 1997; Clark et al., 2008; 
Hellman et al., 2008; Chacon-Heszele et al., 2014). Targeted knock-
out studies indicate a role for HGF/Met in kidney development, and, 
relatedly, HGF/Met signaling is a potent stimulator of Wnt signaling, 
a crucial signaling pathway in this process, validating the in vivo 
relevance of this approach (Monga et al., 2002; Bridgewater et al., 
2008; Ishibe et al., 2009).
Here we report that GRHL2 promoted cystogenesis but sup-
pressed tubulogenesis. GRHL2 protein interacted functionally with 
p300, inhibiting its HAT activity and transcriptional activation of tar-
get genes, including matrix metalloproteases. A small (13 amino 
acids [aa]) sequence of GRHL2 was important for inhibition of p300, 
suppression of tubulogenesis, and reversal of EMT. These results 
mechanistically position GRHL2, an enforcer of the epithelial default 
phenotype, as an antagonist of p300, a coactivator of differentia-
tion-specific genes, with important ramifications for developmental 
and tumor biology.
RESULTS
GRHL2 suppresses cell scattering and tubulogenesis
In light of the epithelial programming role of GRHL2, we tested 
the effect of HGF on GRHL2 levels in MDCK cells. We found that 
HGF down-regulated the expression of endogenous GRHL2 protein 
levels at early time points (Figure 1A). When constitutively expressed 
in MDCK cells, GRHL2 significantly inhibited HGF-induced cell scat-
tering compared with vector control cells (Figure 1B). Conversely, 
MDCK cells with GRHL2 short hairpin RNA (shRNA) knockdown 
demonstrated enhanced HGF-induced cell scattering; retention of 
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(Snowden et al., 2000). Adenovirus E1a protein repressed the AP-1 
and GAL4/GAL4-p300 reporter activities, but a p300-nonbinding 
mutant of E1a (Ferrari et al., 2014) failed to do so (Supplemental 
Figure S8), validating the p300 dependence of transcription in these 
assays. GRHL2 inhibited the coactivator function of p300 in this assay 
(Figure 3D). As additional negative controls, GRHL2 did not affect 
the ability of a p300-independent GAL4-activator fusion protein 
(VP16-GAL4; Kutluay et al., 2009) to activate the same reporter; an-
other transcription factor unrelated to GRHL2, c-Myc, failed to inhibit 
GAL4-p300 function in this assay (Supplemental Figure S9). These 
results indicated that GRHL2 was a potent suppressor of p300 func-
tion. The highly related GRHL1 and GRHL3 proteins had similar ef-
fects in the reporter assay (Supplemental Figure S10).
GRHL2 inhibits the histone acetyltransferase activity 
of p300
The HAT domain of p300 acetylates numerous substrates, in-
cluding lysines 18 and 27 in the N-terminal tail of histone 3 
(H3; Ogryzko et al., 1996; Kasper et al., 2010; Jin et al., 2011). Using 
recombinant proteins, we found that GRHL2 inhibited acetylation of 
H3K27 by p300 in a dose-dependent way in vitro (Figure 4A). We 
found similar results using the p300 HAT domain alone (aa 1283–
1673) rather than full-length p300 (Supplemental Figure S11). Re-
combinant GRHL1 and GRHL3 proteins also inhibited the HAT activ-
ity of p300 (Supplemental Figure S12).
To confirm these in vitro effects in cells, we analyzed histone 
acetylation by chromatin immunoprecipitation (CHIP)–qPCR using 
GRHL2 inhibits p300 function
The AP-1 transcription factor family is important in the regulation of 
most MMP genes (Clark et al., 2008). GRHL2 significantly sup-
pressed AP-1 activity on minimal reporter constructs in HT1080 and 
293 cells (Figure 3A). GRHL2 did not appear to affect the expression 
of FOS or JUN family members after HGF induction (Supplemental 
Figure S6).
In light of the functional similarities between adenovirus E1a and 
GRHL2 (see Discussion), we compared a published list of genes that 
E1a down-regulated through p300 interaction (Ferrari et al., 2014) 
against our list of GRHL2–down-regulated genes; the latter list was 
derived from the RNA-Seq analysis that we performed on GRHL2-
expressing human mesenchymal subpopulation (MSP) cells (Farris 
et al., 2016) and used because a comparison of canine versus human 
gene lists proved uninformative for technical reasons. About 43.5% 
of the genes that E1a repressed through p300 were also repressed 
by GRHL2 (Figure 3B). Downstream Effector Analysis/Ingenuity 
Pathway Analysis revealed that the expression of GRHL2 suppressed 
the regulation of numerous p300-associated genes that were up-
regulated or down-regulated by HGF in the absence of GRHL2 ex-
pression (Figure 3C and Supplemental Figure S7). These results sug-
gested that GRHL2 could potentially inhibit p300 function.
To investigate this, we assayed the effect of GRHL2 on the activity 
of a GAL4-DNA binding domain–p300 fusion protein by transient 
transfection using a GAL4-responsive luciferase promoter, an estab-
lished method for testing p300 coactivator function without con-
founding effects from primary DNA-binding activator proteins 
FIGURE 1: GRHL2 suppresses HGF-induced cell scattering and tubulogenesis and is down-regulated by HGF. (A) HGF 
induction down-regulates endogenous GRHL2 protein. Western blot and densitometric quantitation of HGF treatment 
time course in MDCK cells. HGF induction down-regulates endogenous GRHL2 mRNA in MDCK cells; qPCR results 
expressed as ratios compared with vector control. (B) Constitutive GRHL2 expression in MDCK cells suppresses 
HGF-induced cell scattering; images represent representative morphologies of cells treated for 42 h. (C) GRHL2 
knockdown in enhanced HGF-induced cell scattering (16 h), but MDCK shGRHL2 cells did not undergo an EMT 
phenotypic change when EMT markers were examined via Western blotting. (D) Constitutive GRHL2 expression in 
MDCK cells prevents tubulogenesis (blue, nuclei; green, actin). Scale bar, 20 μm. Quantification of percentage of cysts 
that demonstrated tubulogenesis.
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the IRF-3 binding domain (IBID; aa 2050–2096) that mediates the 
interaction with the p160 coactivator family, including the family 
member steroid receptor coactivator-1 (SRC-1; Sheppard et al., 
2001). Whereas neither the IBID domain of p300 nor SRC-1 alone 
activated transcription efficiently, the combination of both acti-
vated transcription, as reported previously (Figure 5C; Sheppard 
et al., 2001). GRHL2 potently inhibited transcription that was driven 
by the complex of p300-IBID and SRC-1 (Figure 5D). Of interest, 
mutation of the two lysines (K2086 and K2091) of the IBID domain 
that are acetylated in vivo abrogated the ability of the p300-IBID/
SRC1 complex to activate transcription (Figure 5E). These results 
indicate that the transcriptional activation by the p300 C-terminus, 
which is supported by SRC-1 and abrogated by GRHL2, depends 
on acetylation of at least these (and probably other) lysines by p300 
HAT or perhaps other GRHL2-sensitive HATs that remain to be 
determined.
the human cell line HT1080 (because Encode reference data re-
porting histone acetylation are available for the human genome). 
Consistent with the in vitro results, the acetylation of H3K27 was 
inhibited in HT1080 cells expressing GRHL2 constitutively, specifi-
cally on promoters that GRHL2 repressed, including MMP1, 
MMP14, MMP2, and ZEB1; acetylation of GRHL2-up-regulated 
gene promoter–associated H3K27 was either not affected (CDH1, 
ESRP1) or up-regulated (RAB25; Figure 4B). Unlike the effect of E1a 
on p300, there was neither an effect of GRHL2 on global H3 acety-
lation nor global chromatin condensation, as assayed by Western 
blotting (Figure 4B) or immunofluorescence localization of a LacI-
mCherry-GRHL2 protein (Ferrari et al., 2014), respectively (Supple-
mental Figure S13).
GRHL2 interacted with p300 by the criteria of coimmunoprecipi-
tation of transiently cotransfected genes or of endogenous proteins 
(Figure 4C). The recombinant proteins interacted only weakly, how-
ever (Supplemental Figure S14), suggesting that the interaction is 
transient or requires posttranslational modifications absent from our 
recombinant proteins.
GRHL2 inhibits the C-terminal transactivation domain 
of P300
Multiple domains of p300 can coactivate transcription indepen-
dently. One of these is the C-terminal domain (aa 1665–2414), 
which interacts with the p160 family of coactivators (Stiehl et al., 
2007). Previous reports suggested that the activity of the C-terminal 
domain is stimulated by autoacetylation catalyzed by the p300 HAT 
domain (Stiehl et al., 2007). In light of the HAT-inhibitory effect of 
GRHL2 described above, we hypothesized that GRHL2 inhibited 
the C-terminal domain through this mechanism. We confirmed that 
transcriptional activation by the C-terminal domain, assayed as a 
GAL4-C-term fusion protein, was stimulated by a cotransfected 
p300 HAT domain and that the latter domain had no detectable 
ability to activate transcription independently (Figure 5A). GRHL2 
inhibited the enhanced transactivation by the p300 C-terminal do-
main in the presence of cotransfected p300 HAT (Figure 5B). Em-
bedded within the C-terminal domain is a small subdomain called FIGURE 2: GRHL2 suppresses the induction of MMP genes and MMP 
promoters by HGF. (A) GRHL2 suppresses the induction of MMP 
genes (qPCR analysis; EN, endogenous GRHL2; CE, constitutively 
expressed GRHL2; KD, GRHL2 shRNA knockdown). (B) GRHL2 
suppresses the induction of MMP promoters by HGF. HT1080 cells 
were cotransfected with either MMP1 or MMP14 promoter-luciferase 
reporter constructs and GRHL2, E1A, or empty expression vectors. 
Values represent relative luciferase activity normalized to TK-β-
galactosidase control.
Gene 
regulated by 
GRHL2
Fold change 
(shGRHL2+HGF/
GRHL2+HGF) Significance
MMP-1 31.7 Interstitial collagenase, 
necessary for MDCK tubu-
logenesis, p300-dependent 
expression
MMP-9 5.8 Gelatinase B, p300-depen-
dent cancer invasiveness, 
up-regulated in EMT
MMP-13 15.1 Collagenase 3, necessary 
for MDCK tubulogenesis, 
p300-dependent expression
MMP-14 5.82 Membrane-type MMP, 
involved in EMT regulation 
and invasiveness phenotype
MMP-19 3.5 Increases invasion in 
multiple cancers
MMP-24 9.6
TABLE 1: HGF-induced MMP expression in the absence versus the 
presence of GRHL2.
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GRHL2, and GRHL3 (Kokoszynska et al., 
2008). A GRHL2 Δ425-437 construct (with a 
synthetic nuclear localization signal) was un-
able to repress an AP-1-promoter, GAL4-
P300 transactivation (assayed on a GAL4-Luc 
reporter), the MMP1 promoter, or the MMP14 
promoter (Figure 6D). We recently reported 
that GRHL2 repressed the expression of the 
glutamate dehydrogenase-1 gene (GLUD1), 
with important consequences for metabolism 
and anoikis (Farris et al., 2016). Of interest, 
GRHL2 also repressed this promoter in a 
manner that required aa 425–437 
(Supplemental Figure S17). GRHL2 Δ425-437 
was still able to interact, however, with p300 
in a cotransfection assay (Supplemental 
Figure S18).
We hypothesized that the inhibition of 
p300 function could provide a mechanism 
for some aspects of transcriptional repro-
gramming by GRHL2. Consistent with the 
inability of the GRHL2 Δ425-437 to repress 
the AP1-dependent promoters MMP1 and 
MMP14 (Figure 6C), this mutant was unable 
to suppress HGF-induced tubulogenesis in 
MDCK cells (Figure 7A). Moreover, wild-
type GRHL2 reverses EMT in MSP cells, a 
cancer stem cell–like subpopulation derived 
from the mammary epithelial cell line HMLE 
(Cieply et al., 2012, 2013). The GRHL2 
Δ425-437 mutant failed to reverse EMT by 
the criteria of cell morphology as well as 
EMT marker protein and mRNA expression 
(Figure 7B). These results indicated that the 
inhibition of p300 by GRHL2 contributes 
significantly to transcriptional reprogram-
ming involved in both tubulogenesis and 
EMT (Figure 8).
DISCUSSION
Previously we proposed that the epithelial 
cell is the default phenotype from both de-
velopmental and cancer biological points of 
view. Under this hypothesis, the epithelial 
phenotype is adopted automatically by a cell 
in the absence of genomic/epigenetic altera-
tions or inductive differentiation signaling 
(Frisch, 1997). Consistent with this idea, E-cadherin–expressing cells 
are the first to emerge at the late-two-cell stage; these eventually 
give rise to all differentiated cell types of the adult organism (Hyafil 
et al., 1980; Vestweber and Kemler, 1985; Fleming et al., 1989; Larue 
et al., 1994). The adenovirus-5 E1a protein, which interacts with and 
negatively modulates p300, enforces an epithelial phenotype, sup-
presses EMT, enhances anoikis, suppresses MMP expression, and 
exerts a ubiquitously acting tumor suppression effect in human tumor 
cells (Frisch and Mymryk, 2002).
The default idea has been invoked in recent studies from other 
laboratories to explain, for example, MET occurring at metastatic 
sites (Thiery and Sleeman, 2006; Polyak and Weinberg, 2009; Tam 
and Weinberg, 2013). The default hypothesis could be explained 
molecularly if critical coactivators such as p300 were required for 
differentiation-specific but not epithelial-specific gene expression 
A small region of GRHL2 inhibits p300 and is critical 
for suppressing tubulogenesis and EMT
To identify the region of GRHL2 responsible for p300 inhibition, whole 
domains of GRHL2 were deleted initially (Figure 6A) and assayed for 
inhibition of HAT activity and transcriptional activation by GAL4-p300. 
In light of the lack of GRHL2-binding sites in most GRHL2-repressed 
promoters (unpublished data), the surprising result was that the DNA-
binding domain (aa 245–494) was critical for inhibition (Supplemental 
Figures S15 and S16). Glutathione S-transferase (GST)–GRHL2 protein 
subfragments derived from the DNA-binding domain were assayed 
for HAT inhibition (Figure 6B). The region of aa 325–475, and within 
that, the 13-aa sequence 425–437, inhibited HAT activity potently 
(Figure 6C), and a synthetic peptide (aa 420–442) was also able to in-
hibit p300 HAT activity (Supplemental Figure S15C). The aa 425–437 
fragment (IRDEERKQNRKKG) is an α-helix conserved among GRHL1, 
FIGURE 3: GRHL2 suppresses AP-1 and p300 function. (A) GRHL2 suppresses AP1 function. 
HT1080 and 293T cells were cotransfected with AP-1 response element-luciferase reporter 
construct and GRHL2 expression vector or empty vector. PMA was used to induce AP-1 
signaling in 293T cells. Values represent relative luciferase activity normalized to TK-β-
galactosidase control. (B) Venn diagram comparing GRHL2-repressed genes (Farris et al., 2016) 
vs. p300 target genes identified via E1a (Ferrari et al., 2014). (C) GRHL2 suppresses the p300 
pathway. p300 effector and target genes induced by HGF in MDCK cells with GRHL2 shRNA vs. 
cells with constitutive GRHL2 determined by Ingenuity Pathway Analysis. Quantitation of the 
number of unregulated, HGF up-regulated, or HGF down-regulated genes for both cell lines. 
The p300 interactome diagram on which this is based is shown in Supplemental Figure S7. 
(D) GRHL2 suppresses p300 function. GAL4-minimal promoter-luciferase activation by a 
cotransfected GAL4-p300 was assayed in HT1080 cells in the presence or absence of 
cotransfected GRHL2 expression vector; values represent relative luciferase activity normalized 
to TK-β-galactosidase control.
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1999; Sun et al., 2004; Chou et al., 2006; 
Clark et al., 2008; Lee and Partridge, 2010; 
Santer et al., 2011).
With regard to tubulogenesis, the p300-
dependent Ets family transcription factors 
Etv4 and Etv5 are key transcriptional regula-
tors of this developmental process (Yang 
et al., 1998; Jayaraman et al., 1999; Goel 
and Janknecht, 2003; Foulds et al., 2004; Lu 
et al., 2009; Oh et al., 2012; Wollenick et al., 
2012). In addition, the family of p300-de-
pendent TCF/β-catenin transcription com-
plexes is a central hub for Wnt signaling, 
crucial for nephron induction (Li et al., 2007; 
Bridgewater et al., 2008; Miller and McCrea, 
2010; Ma et al., 2012).
p300 activates transcription through an 
array of mechanisms: acetylation of his-
tones, acetylation of transcription factors, 
binding of the p300 bromodomain to acet-
ylated histones to promote transcriptional 
activity, and recruitment of histone methyl-
transferases (e.g., Set1b complex; Ogryzko 
et al., 1996; Gu and Roeder, 1997; Mizzen 
and Allis, 1998; Ito et al., 2001; Wolf et al., 
2002; Stiehl et al., 2007; Chen et al., 2010; 
Tang et al., 2013). By inhibiting p300 HAT 
activity, GRHL2 could enforce an inactive 
state on p300 in at least two ways. First, 
p300 HAT activity is substantially increased 
by autoacetylation of an autoinhibitory 
loop on the HAT domain, which GRHL2 
would suppress, stably inhibiting the en-
zyme (Thompson et al., 2004). Second, the 
p300 HAT domain potentiates p300 C-terminal domain (aa 1665–
2414) transactivation (Stiehl et al., 2007), which GRHL2 blocked. 
The minimal domain for p300 C-terminal transactivation is aa 
2000–2180, which include the IBID (Lin et al., 2001; Matsuda 
et al., 2004). The p300 IBID domain cooperates with SRC1, a 
p160/steroid receptor coactivator family member, to activate tran-
scription (Sheppard et al., 2001). By inhibiting the HAT activity of 
p300, GRHL2 suppresses coactivation by the p300-IBID complex, 
which is highly dependent on the two known acetylation sites, 
K2086 and K2091, for activity. Of interest, SRC1-p300 was shown 
to induce TWIST expression and EMT in breast cancer (Qin et al., 
2009), and GRHL2 is a potent EMT suppressor.
Although >400 DNA-binding proteins interact with p300 and 
use it as a coactivator, the inhibitory effect of GRHL2 on p300 is 
nearly unique, shared by only one other family of proteins, the E1a-
like inhibitor of differentiation (EID) proteins. EID1 inhibits p300 HAT 
activity (MacLellan et al., 2000), and EID3 blocks the SRC-1/CBP in-
teraction; the mechanism of EID2 is controversial (Ji et al., 2003; 
Miyake et al., 2003; Båvner et al., 2005). To our knowledge, the 
effects of EID proteins on EMT or tubulogenesis have not been 
investigated.
GRHL2 regulates intracellular metabolism, and this could indi-
rectly affect p300 by altering the levels of the cofactors for p300 
HAT, acetyl-CoA, or crotonyl-CoA (Li and Li, 2015; Farris et al., 
2016). This may provide an additional, more indirect mechanism for 
GRHL2 to affect p300 function.
In summary, p300 and related coactivators are crucial for cells to 
differentiate. Under the default-phenotype hypothesis, this can be 
(Frisch, 1997). Accordingly, we reported previously that GRHL2, 
shown here to antagonize the coactivator p300, inhibits and re-
verses the oncogenic EMT, suppressing tumor initiation, drug resis-
tance, and anoikis resistance (Cieply et al., 2012, 2013).
The novel observation that GRHL2 antagonizes p300-depen-
dent pathways in the context of tubulogenesis provides a poten-
tially unifying mechanism for both the developmental and onco-
logic effects of GRHL2. GRHL2 probably regulates tubulogenesis 
by additional, p300-independent mechanisms. For example, 
cells that fail to down-regulate GRHL2 appropriately may fail to 
down-regulate cell adhesion molecules in response to morpho-
genic factors (Werth et al., 2010; Senga et al., 2012). For exam-
ple, E-cadherin relocalizes from cell junctions to diffuse mem-
brane pattern in protrusive cell extensions during tubulogenesis; 
this relocalization might be envisioned to require GRHL2 down-
regulation and subsequent loss of junctional complex compo-
nents in these specific cells (Pollack et al., 1998).
p300 contributes to tubulogenesis and cancer-related EMT in 
multiple important ways, providing a mechanism for GRHL2, via in-
hibition of p300, to suppress these processes. With regard to can-
cer, transcription factors that use p300/CBP and additional coactiva-
tors that interact with p300/CBP have been implicated in the 
oncogenic EMT, tumor drug resistance, and tumor recurrence 
(Matthews et al., 2007; Qin et al., 2009; Santer et al., 2011; Zhou 
et al., 2012; Delvecchio et al., 2013; Ringel and Wolberger, 2013; 
Yang et al., 2013; Xu et al., 2014; Cho et al., 2015). The up-regula-
tion of MMPs associated with the oncogenic EMT requires AP-1, 
Ets, and other p300-dependent factors (Westermarck and Kähäri, 
FIGURE 4: GRHL2 suppresses the HAT activity of p300. (A) In vitro HAT assays with 
recombinant H3, p300, and GRHL2 proteins. Coomassie stains to assess the quality of 
recombinant proteins used throughout this study are shown in Supplemental Figure S19. 
(B) GRHL2 inhibits the acetylation of H3 on GRHL2-repressed but not GRHL2-induced 
promoters in vivo (ChIP assay). Cross-linked chromatin from HT1080+ vector HT-1080+GRHL2 
cells immunoprecipitated with H3K27-Ac or rabbit IgG; the indicated promoters were assayed 
for H3K27Ac by qPCR using the primers in Materials and Methods. *p < 0.05. GRHL2 does not 
affect global histone H3K18-Ac or H3K27-Ac (Western blotting of total histones). (C) GRHL2 
interacts with p300. Left, cotransfection of indicated expression constructs, followed by 
coimmunoprecipitation/Western blotting. Middle, coimmunoprecipitation of retrovirally 
expressed, S-tagged GRHL2 with endogenous p300. Right, coimmunoprecipitation of 
endogenous GRHL2 and endogenous P300.
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extended to critical roles in EMT in contexts such as tubulogenesis 
and oncogenesis. The inhibition of p300 by GRHL2 provides a 
mechanism for GRHL2 to enforce the default epithelial 
phenotype.
MATERIALS AND METHODS
Cell lines
The 293 HEK cells without T antigen (Doug Black, University of 
California, Los Angeles [UCLA], Los Angeles, CA), MDCK cells 
(clone M8; Frisch and Francis, 1994), and HT1080 cells (American 
Type Culture Collection [ATCC], Manassas, VA) were cultured in ad-
vanced DMEM (Life Technologies, Carlsbad, CA) with 10% fetal bo-
vine serum (FBS; Hyclone, Chicago, IL) and 1× penicillin-streptomy-
cin-glutamine (PSG) (Invitrogen, Carlsbad, CA). miMCD-3 cells 
(ATCC) were cultured in advanced DMEM:Ham’s F-12 (Life Tech-
nologies) with 10% FBS and 1× PSG. The HMLE and HMLE MSP 
cells were described previously (Cieply et al., 2013).
Generation of stable cell lines by retroviral transduction 
and lentiviral transduction
Full-length GRHL2/pMXS-IRES-Puro and retroviral packaging pro-
tocol were described previously (Farris et al., 2016). GRHL2 Δ425-
437 was subcloned into pMXS-IRES-Puro from GRHL2 Δ425-437-
NLS-3xFLAG/pCDNA3.1+. GRHL2 shRNA/pGipZ and scramble 
control shRNA/pGipz were obtained from Open Biosystems and 
packaged as previously described (Cieply et al., 2012). The shRNA 
construct in pTRIPZ was made by subcloning an MluI-XbaI fragment 
from pGIPZ.
Cell scattering assays
MDCK cells were plated on collagen-coated six-well dishes to give 
25% cell confluency on HGF induction. Cells were treated with 
60 ng/ml recombinant human HGF (RD Systems, Minneapolis, MN) 
in DMEM or fresh DMEM for the time periods indicated. The cells 
were imaged and then harvested for protein or RNA analysis. Im-
ages were obtained using a Zeiss Axiovert 200M, AxioCam MRM 
camera, Phase 20×/0.55 objective, room temperature, and Axio-
Vision, release 4.8 software. Cell scattering time-lapse movies were 
taken every 15 min over a 24-h period. Time-lapse images were 
obtained using a Nikon Eclipse TE2000-E with Photometrics Cool-
SNAP HQ2 Monochrome charge-coupled device with a Phase 
40×/0.75 objective using a Bioptechs Delta T4 Culture Dish Heater, 
Prior ProScan II Encoded Motorized Stage, and Oko Labs Digital 
Stage Top Incubator (37°C/5% CO2). For each data point, four 40× 
images were stitched together using 10% overlap with background 
correction in NIS-Elements AR (Nikon).
Western blotting
Protein lysates were incubated at 95°C for 5 min in 1× SDS lysis buf-
fer (125 mM Tris-HCl, pH 6.8, 0.04% SDS, 0.024% bromophenol 
blue, 5% β-mercaptoethanol, and 20% glycerol). SDS–PAGE was 
run in a 4–20% gradient Novex Tris-glycine gel (Invitrogen). Proteins 
were electrophoretically transferred to a polyvinylidene difluoride 
FIGURE 5: GRHL2 inhibits the C-terminal transactivation domain of 
p300. (A) The p300 HAT domain stimulates transactivation by the 
p300 C-terminus (cotransfection in HT1080 cells). (B) GRHL2 inhibits 
transactivation by the p300 C-terminus. HT1080 cells were 
cotransfected with GAL4 response element luciferase reporter in the 
presence of the indicated expression constructs. (C) The IBID domain 
of p300 and the coactivator SRC-1 synergize to activate transcription. 
HT1080 cells were cotransfected with GAL4 response element 
luciferase reporter I in the presence of the indicated expression 
constructs. (D) GRHL2 inhibits transactivation by the IBID-SRC-1 
complex. HT1080 cells were cotransfected with GAL4 response 
element luciferase reporter in the presence of the indicated 
expression constructs. (E) Transactivation by the IBID-SRC-1 complex 
is contingent upon lysines 2086 and 2091. HT1080 cells were 
cotransfected with GAL4 response element luciferase reporter in the 
presence of the indicated expression constructs. In A–E, values 
represent relative luciferase activity normalized to TK-β-galactosidase 
control. (F) Schematic of p300 domains. Bd, bromodomain; HAT, 
histone acetyltransferase domain; IBID, IRF-3 binding domain; KIX, 
CREB-binding domain.
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MDCK tubulogenesis assay
MDCK tubulogenesis assay was performed 
as previously described (Elia and Lippincott-
Schwartz, 2009). Briefly, collagen matrix was 
made by mixing 10× MEM (Invitrogen), 100× 
PSG, 23.5 g/l NaHCO3 (Invitrogen), sterile 
water, and 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (Invitrogen) to work-
ing concentrations. Vitrogen bovine colla-
gen (5005-b; Advanced Biomatrix, Carlsbad, 
CA) was added to a final concentration of 2 
mg/ml. NaHCO3 was used to bring the solu-
tion to pH 7.3 via a pH strip indicator (Elia 
and Lippincott-Schwartz, 2009). In a 24-well 
plate, 100 μl of working collagen solution 
was placed in a 1.0-μm-pore cell culture in-
sert (Falcon, Franklin Lakes, NJ) and allowed 
to solidify for 3 h in tissue culture incubator. 
Subconfluent MDCK cells were trypsinized 
and counted using a Countess Cell counting 
machine (Invitrogen). Cells were pipetted 
into the working collagen solution to give a 
final concentration of 5000 cells/ml. Then 
250 μl of cell/collagen solution was pipetted 
onto the presolidified collagen matrix in the 
cell culture insert. The cell–collagen matrix 
was allowed to solidify for 2 h at 37°C and 
5% CO2, and then 250 and 500 μl of me-
dium was placed on the cell–collagen matrix 
cell culture insert and in a 24-well chamber, 
respectively. Media were changed every 3 d. 
After 6 d, 60 ng/ml recombinant human 
HGF was added to indicated wells, and 
branching morphogenesis was monitored 
by microscopy. MDCK cyst staining was per-
formed as previously described (Elia and 
Lippincott-Schwartz, 2009), with the only 
modification being the substitution of 7 mg/
ml fish-skin gelatin for Triton X-100 in per-
meabilization buffer. Cysts were stained with 
Alexa Fluor 488–phalloidin (Molecular Probes, Eugene, OR) and 
Hoescht 33258 (Molecular Probes). Representative 2-d post-HGF 
images were obtained using a Zeiss 710 Confocal with Airyscan, 
Apochromat 40×/1.2 W Autocorr M27, room temperature, Axio-
Observer.Z1 software, and diode 405-nm and argon 488-nm lasers. 
Images were processed in Photoshop (Adobe). Tubulogenesis was 
observed by day 2 after HGF addition and quantified on day 5 after 
HGF addition.
RNA-Seq Assay
MDCK+GRHL2/pMXS and MDCK+shGRHL2/Gipz cells were plated 
in collagen-coated, 60-mm2 dishes to obtained 25% confluency 
upon HGF treatment. Cells were treated with either 60 ng/ml HGF 
in DMEM complete or DMEM complete alone for 24 h; RNA was 
isolated from all four treatment conditions in triplicate using the 
RNeasy Plus Kit (Qiagen) and quantified using NanoDrop (Fisher, 
Waltham, MA). Raw data were aligned to the CanFam3 reference 
genome using TopHat2 (Kim et al., 2013). For each sample and each 
gene, the number of reads generated from that sample and 
mapping to that gene were counted using RSamtools. Genes were 
as defined in the ensembl database, version 82 (Cunningham et al., 
2015). The resulting count table was analyzed using DESeq 
membrane (Immobilon, Waltham, MA) in Tris-glycine buffer with 5% 
methanol. Membranes were blocked for 1 h in 1× Tris-buffered 
saline (TBS) plus 5% nonfat milk. Primary and secondary antibodies 
were incubated in 1× TBS plus 5% nonfat milk plus 0.1% Tween-20. 
Primary antibodies were incubated for 2 h at room temperature or 
overnight at 4°C at 1:1000 dilution. Primary antibodies used were 
as follows: GRHL2, rabbit (rb; Sigma-Aldrich, St. Louis, MO); β-actin, 
mouse (ms; Thermo Pierce); fibronectin, ms (BD Biosciences, Frank-
lin Lakes, NJ); vimentin, ms (Santa Cruz Biotechnology, Dallas, TX); 
β-actin, ms (Sigma-Aldrich); E-cadherin, ms (BD Biosciences); β-
catenin, ms (BD Biosciences); glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), ms (OriGene, Rockville, MD); acetyl-lysine, rb 
(Millipore); H3K18AC, rb (Cell Signaling, Danvers, MA); H3K27AC, 
rb (Cell Signaling); total H3, rb (Cell Signaling); GST, ms (Thermo 
Pierce, Waltham, MA); p300, rb (sc-584; Santa Cruz Biotechnology); 
p300, rb (sc-585; Santa Cruz Biotechnology); FLAG, ms (Sigma-Al-
drich); and GAL4, rb (Santa Cruz Biotechnology). Goat anti-rabbit or 
anti-mouse horseradish peroxidase–conjugated secondary anti-
bodies (Bio-Rad) were used at 1:3000 dilution and incubated for 1 
h at room temperature RT. Western blot membranes were devel-
oped using ECL-West Pico (Pierce) and analyzed using standard 
chemiluminescence techniques.
FIGURE 6: A small region within the DNA-binding domain of GRHL2, aa 425–437, inhibits p300. 
(A) Schematic of GRHL2 domains. DBD, DNA-binding domain; DD, dimerization domain; TAD, 
transactivation domain. (B) HAT assays using the indicated GRHL2 fragments, assayed as 
GST-fusion proteins. (C) GRHL2 aa 425–437 inhibits p300 HAT activity. The indicated fragments 
derived from GRHL2 were assayed as GST-fusions (left) or recombinant peptides (right) for 
inhibition of HAT activity. (D) GRHL2 aa 425–437 are required for inhibition of an AP-1 reporter, 
GAL4 reporter in conjunction with GAL4-p300, MMP1 reporter, or MMP14 reporter. Values 
represent relative luciferase activity normalized to TK-β-galactosidase control.
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(Anders and Huber, 2010) with two independent comparisons: sam-
ples with HGF compared with those without or with GRHL2 overex-
pressed, and samples with HGF compared with those without, both 
expressing GRHL2 shRNA. Genes were considered differentially 
expressed if they showed a false discovery rate of ≤0.05 and a fold 
change of ≥1.5 in either direction. Genes regulated by HGF with 
shRNA against GRHL2 but not regulated by HGF with GRHL2 over-
expressed were uploaded to Ingenuity Pathway Analysis (Qiagen), 
where a Core Analysis was performed using default settings.
Quantitative reverse transcription PCR analysis
MDCK parent, GRHL2/pMXS, and shGRHL2/pGipZ cells were plated 
on collagen-coated 60-mm2 dishes and treated as indicated. Cells 
were harvested using RNEasy Plus minikit (Qiagen, Hilden, Germany), 
analyzed using NanoDrop, and converted to cDNA using SuperScript 
FIGURE 7: The p300-inhibitory domain of GRHL2 is important for the suppression of tubulogenesis and reversion of 
EMT. (A) MDCK cells expressing GRHL2 wild-type or GRHL2 Δ425-437 were assayed for tubulogenesis (blue, nuclei; 
green, actin). Scale bar, 20 μm. Middle, quantitation; right, Western blot confirmation of protein levels. (B) MSP cells 
expressing GRHL2 wild-type or GRHL2 Δ425-437 were assayed for reversion of EMT by Western blotting for EMT 
markers (left), cell morphology (middle), or qPCR (right).
FIGURE 8: GRHL2 suppresses tubulogenesis and EMT by inhibition 
of p300.
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1674), GAL4- p300C-terminus (aa 1665–2414), and GAL4- p300 
IBID (aa 2050–2096) were generated by subcloning PCR fragments 
(MluI-NotI) into pBIND (Promega). Primer sequences were p300 
C-terminal-F (TATATAACGCGTATCGCTTTGTCTACACCTGCAAT), 
p300 C-terminal-R (TTTAAAGCGGCCGCCTAGTGTATGTCTAGT-
GTAC), p300 HAT-F (TATATAACGCGTATAGGAAAGAAAATAAG-
TTTTCT), p300 HAT-R (TTTAAAGCGGCCGCCTAGTCCTGGCTCT-
GCGTGTGCAG), p300 IBID-F (TATATAACGCGTATGCCTTA-
CAAAACCTTTTGCG), and p300 IBID-R (TTTAAAGCGGCC-
GCCTAATTAGAGTTGGCA TACTTGG). To generate the p300-IBID 
mutant (K2086A and K2091A), the p300 IBID lysine nucleotide 
sequences were mutated to alanine, and flanking Mlu1 and Not1 
restriction enzymes were added to the 5′ and 3′ ends, respectively. 
The sequence was then generated as a gBlock gene fragment 
(IDT). The p300 mutant sequence was 5′ CACAACCAGG 
ATTGGGCCAG GTAGGTATCA GCCCACTCGC ACCAGGCACT 
GTGTCTCAAC AAGCCTTACA AAACCTTTTG CGGACTCTCA 
GGTCTCCCAG CTCTCCCCTG CAGCAGCAAC AGGTGCTTAG 
TATCCTTCAC GCCAACCCCC AGCTGTTGGC TGCATTCATC GC-
GCAGCGGG CTGCCGCGTA TGCCAACTCT AATCCACAAC 3′. 
The IBID mutant fragment was digested and ligated into pBIND 
vector. HA-SRC1/pACTAG was a generous gift from Timothy Beis-
chlag (Simon Fraser University, Burnaby, Canada).
Immunoprecipitation
GRHL2-STAP contained full-length human GRHL2 fused to a C-ter-
minal myc–streptavidin binding peptide (SBP)–S-tag sequence de-
rived by ligating a synthetic oligonucleotide containing the S-tag to 
a PCR product containing the myc-SBP tags from the pCeMM-CTAP 
vector (Burckstummer et al., 2006). The 293 NOT cells were plated 
on collagen-coated six-well dishes and transfected using 1 μg of 
empty vector/pCDNA3.1+ or GRHL2-S-TAP/pCDNA3.1+ and 1 μg 
of empty vector/VR1012 or p300/VR1012) with 6 μl of Lipofectamine 
(Invitrogen) in 300 μl of Opti-MEM (Invitrogen). Cells were incubated 
for 4–6 h with DMEM and then refed with DMEM. At 28 h posttrans-
fection, cells were lysed in 600 μl of cold p300 lysis buffer (25 mM 
Tris-HCl, pH 8, 75 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.1% NP-
40, and protease inhibitor tablet [Roche, Basel, Switzerland]). Sample 
lysates were passed through a 1-ml syringe with a 27-gauge needle 
three times and precleared in a 4°C microcentrifuge at 13,200 rpm 
for 10 min. Total lysate samples were obtained, mixed 1:1 with 2× 
SDS lysis buffer (250 mM Tris-HCl, pH 6.8, 0.08% SDS, 0.048% bro-
mophenol blue, 10% β-mercaptoethanol, 40% glycerol) and heated 
for 5 min at 95°C. Lysates were precipitated for 2 h with 40 μl of 50% 
S protein-agarose (EMD Millipore, Billerica, MA) that had been pre-
equilibrated with p300 lysis buffer containing 10 mg/ml bovine se-
rum albumin (BSA). Immunoprecipitation lysates were washed three 
times with p300 lysis buffer, diluted with 2× SDS lysis buffer, and 
heated for 5 min at 95°C. Lysates were processed using previously 
described Western blotting methods. For endogenous p300 and ec-
topic GRHL2 coimmunoprecipitation, MSP cells with empty vector/
pMXS or GRHL2/pMXS were used in the experiment. For endoge-
nous p300 and endogenous GRHL2 coimmunoprecipitation, paren-
tal HMLE cells were used in the experiment. The coimmunoprecipi-
tation method was identical between the different cell lines. For each 
cell line, two 100-mm dishes were grown to 80% confluency, washed 
twice with cold PBS, lysed in 1 ml of p300 lysis buffer with protease 
inhibitors, and passed three times through a 27-gauge needle. After 
lysates were precleared at 13,200 rpm, 10 μg of p300 antibody 
(SCBT, SC-584) or rabbit immunoglobulin G (IgG; Jackson, Bar 
Harbor, ME) was added to lysates and incubated overnight on a 4°C 
wheel. Preequilibrated Protein A-Sepharose (45 μl; GE Healthcare) 
III First-Strand Synthesis SuperMix (Invitrogen) with oligo dT primers 
and 1 μg of RNA. cDNA was analyzed using SYBR Green PCR Master 
Mix on an Applied Biosystems 7500 Real Time PCR System. Values 
reported were determined using the ΔΔCT method using canine 
CBX1 as internal control. Primers were as follows: CBX1-F (AAG-
TATTGCAAGGCCACCCA), CBX-R (TTTTCCCAATCAGGCC CCAA), 
GRHL2-F (TTCCTCCCCAGGAGAGATGG), GRHL2-R (GG-
CCCAACACACGGATAAGA), MMP1-F (TGACTGGAAAGGTCGA-
CACG), MMP1-R (GACCTTGGTGAAGGTCAGGG), MMP3-F (CTG-
ACCC TAGCGCTCTGATG), MMP3-R (GTCCTGAGGGATTTTC-
GCCA), MMP13-F (GGACTTCCCAGGGATTGGTG), MMP13-R (AT-
GACACGGACAATCCGCTT), MMP14-F (CCCAGAGGAGGGCAT-
GTTTT), MMP14-R (GACTCCCCACCCTTCCAATG), FOS-F (GGGA-
GGACC TTATCTGTGCG), FOS-R (ACACACTCCATGCGTTTTGC), 
FOSL1-F (ACACCCTCCCTGACTCCTTT), FOSL1-R (CTGAAGA-
GGGCAT GGGATTA), FOSB-F (GGAGAAGAGAAGGGTTCGCC), 
FOSB-R (CACAAACTCCAGACGCTCCT), JUN-F (GACCTTCTAC-
GACGATGCCC), JUN-R (TTCTTGGGGCACAGGAACTG), JUNB-F 
(GTGAAGACACTCAAGGCCGA), and JUNB-R (AGACTGGGGG-
AATGTCCGTA).
Luciferase reporter assays
HT1080 or 293 NOT cells were transiently transfected using Lipo-
fectamine 2000 (Invitrogen) at 1 μg of DNA:3 μl of Lipofectamine. 
After 20 min of incubation in 300 μl of Opti-MEM (Invitrogen), 1.0 μg 
DNA was transfected into a 12-well plate with DMEM and refed 4 h 
later with DMEM. After 28–36 h posttransfection, the cells were 
washed twice with cold phosphate-buffered saline (PBS), lysed in 
200 μl of 1× Cell Culture Lysis Buffer (Promega), frozen for at least 
1 h at −80°C, thawed on ice, and centrifuged at 13,200 rpm. The 
supernatants were assayed for luciferase activity (Promega, Madi-
son, WI) and β-galactosidase activity as internal control (2× 
β-galactosidase assay reagent, 200 mmol/l sodium phosphate, 
pH 7.3, 2 mmol/l MgCl2, 100 mmol/l 2-mercaptoethanol, and 
1.33 mg/ml o-nitrophenylgalactoside). MMP1 promoter (−1200 to 
+60) and MMP14 promoter (−1114 to −242) luciferase reporter 
plasmids were generated by subcloning the promoter from ge-
nomic DNA using PCR into the pGL3-basic luciferase reporter 
plasmid. Primer sequences were MMP1prom-F (TTATTACTCG-
AGCCCT CCCTCTGATGCCTCTGA), MMP1prom-R (TATATAAA-
GCTTC TCCAATATCCCAGCTAGGAA), MMP14prom-f (TTATTAC-
TCGA G C CCTTTCTCACGGTCAGCTT), and MMP14prom-R (TAT-
AT AAA GC TTTCTCGCTCTCTCCTCTGGTC). GRHL2/pcDNA3.1, 
TK-LacZ, and E1a/pCDNA3.1 plasmids were described previously 
(Grooteclaes and Frisch, 2000; Cieply et al., 2012). E1A p300 
binding mutant was a generous gift from Arnold Berk (UCLA) sub-
cloned into pCDNA3.1+. GRHL2 Δ425-437 was generated by 
cloning GRHL2 aa 1–424and 438–625 fragments and ligating to-
gether with Bglll and then ligating into pCDNA3.1+ using BamHI 
and Sal1. Primers used were GRHL2-1-424-F (TATATAGGATCCAT-
GTCACAAGAGTCGGACAA), GRHL2-1-424-R (ATATAAAGATCTT-
TTTCTTTCTGCTCCTTTGT), GRHL2-438-625-F (TAAATTAGATCT
AAAGGCCAGGCCTCCCAA AC), and GRHL2-438-625-R (TTATAT-
GTCGACCTAGATTTCCATGAGCGTGA). pGL4.44[luc2P/AP1 RE/
Hygro] (Promega) was used to assay for AP-1–responsive promoter 
activity, and control plasmid was pGL4.27 (Promega). Phorbol 
12-myristate 13-acetate (PMA) induction (10 ng/ml; Thermo Fisher) 
was used for assaying AP-1 activity in transfected 293 cells. Full-
length p300-GAL4/VR1012 and EV-GAL4/VR1012 were generous 
gifts from Neil Perkins (Newcastle University, Newcastle upon 
Tyne, United Kingdom); they were assayed on the GAL4 respon-
sive reporter pG5-Luc (Promega). GAL4- p300 HAT (aa 1283–
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body (Cell Signaling) or rabbit IgG (Jackson) to 3.3 × 106 cell equiva-
lents in ChIP RIPA buffer. 2) Protein A-Sepharose was used instead of 
FLAG-agarose beads. 3) qPCR was performed using 2× SYBR Green 
Master Mix (10 μl; Applied Biosystems, Foster City, CA), 0.08 μl of 
100 mM primer, and 1 μl of ChIP DNA in a 20-μl reaction. Primer 
sequences were as follows: MMP1-1-F (AACCTCAGAGAACCCC-
GAAG), MMP1-1-R (TACTAACACTGCGCACCTGA), MMP1-2-F 
(CAGAGTGGGGCATGAGTAGG), MMP1-2-R (TGTCTTCGGTACTG-
GTGACC), MMP14-F (AAGTAAGTGAGCTTCCCGGC), MMP14-R 
(GGAGTTCGCCCCA GTTGTAA), MMP2-F (TCGCCCATCATCAAG-
TTCCC), MMP2-R (CCCCCAAGCTGTTTACCGAA), ZEB1-1-F (GCG-
AGGCGTGGGA CTGATGG), ZEB1-1-R (AAAGTTGGAGGCTCGGC-
GGC), ZEB1-2-F (CTGCACGGCGATGACCGCT), ZEB1-2-R (TTCC-
GCTTGCCAGCAGCCTC), CDH1-F (ACTCCAGGCTAGAGGGT-
CACC), CHD1-R (CCGCAAGCTCACAGCTTTGCAGTTCC), ESRP1-
F (GGGAGC TTGGTCAAGTCAAC), ESRP1-R (TCTTAAATCGGGC-
CACGCAG), RAB25-F (AGGTCCTGTCCCTTTTTCGC), RAB25-R 
(TTGGGGGTAAGGGGACTTCT), GAPDH-F (ATGGTTGCCACT-
GGGGATCT), and GAPDH-R (TGCCAAAGCCTAGGGGAAGA). 
Results were normalized to GAPDH values.
Ex vivo kidney culture
All experiments involving mice were approved by the West 
Virginia University Institutional Animal Care and Use Committee. 
Hoxb7creEGFP transgenic mice and the ex vivo kidney culture 
method were described previously (Zhao et al., 2004). We re-
moved embryonic kidney at embryonic day 13.5 and cultured 
the kidneys in 1 μM batimastat (Tocris, Bristol, United Kingdom) 
or vector in culture medium for 48 h. Images were taken of GFP 
ureteric buds on an Olympus MVX10 Macro Zoom, ORCA-Flash 
4.0 Monochrome camera, objective 2×, zoom 4×, fluorescein iso-
thiocyanate, and using CellSen Imaging Software. Ureteric buds 
were counted for quantification.
Confocal microscopy of transfected RRE.1 cells
RRE.1 cells, wild-type e1a-NLS-LacI-mCherry, and empty vector 
NLS-LacI-mCherry were generous gifts from Arnold Berk, and the 
experiment was performed as previously described (Verschure 
et al., 2005; Ferrari et al., 2014). GRHL2 was subcloned into empty 
vector NLS-LacI-mCherry using Sal1. Images were taken on a Zeiss 
Axioimager Z1 microscope, LSM 510 confocal, 63×/0.75 LDPlan-
neofluar, 4′,6-diamidino-2-phenylindole and rhodamine, and Zeiss 
Zen software. Images were quantified using mean area on ImageJ 
(National Institutes of Health, Bethesda, MD).
Statistical analysis
Error bars in graphs represent SD. p values were calculated using a 
Student’s two-tailed t test.
was added and incubated for 90 min. Samples were washed three 
times in p300 lysis buffer, 45 μl of 2× SDS lysis buffer was added, and 
samples were heated at 95°C for 5 min. Lysates were processed us-
ing previously described Western blotting methods.
Histone acetylation assays
Histone acetylation reactions contained indicated amounts of re-
combinant baculovirus Flag-tagged p300 (37.5 ng; Active Motif, 
Carlsbad, CA) or baculovirus p300 HAT (1283-1673; Sigma-Aldrich), 
250 ng of H3 (Cayman), 100 μM acetyl-CoA (MP Biomedical, Santa 
Ana, CA), and indicated amounts of PreScission-cleaved GRHL2, 
GST-GRHL2, or GST alone in 30 μl of p300 acetylation buffer 
(50 mM Tris-HCl, pH 8.0, 1 mM dithiothreitol [DTT], 0.1 mM EDTA, 
10% glycerol, and protease inhibitor). Acetylation reactions were 
incubated for 15 min at 30°C on heat block. Reactions were diluted 
with 2× SDS lysis buffer and incubated for 5 min at 95°C. Lysates 
were processed using previously described Western blotting 
methods.
Recombinant protein purification
Full-length GRHL2 was subcloned into pGEX-6P-3 vector (GE 
Healthcare) and transformed into BL21 bacteria (Invitrogen). 
GRHL2 fragments were subcloned into pGEX-6p-3 using BamH1 
and Sal1. A colony was selected and grown in 20 ml of LB+amp 
overnight at 37°C. The next day, 10 ml of culture was inoculated 
into 500 ml of LB+amp and incubated for ∼2 h at 37°C with shak-
ing until OD ≈ 0.6 was obtained. Isopropyl-β-d-thiogalactoside 
was added to final concentration of 0.1 mM and incubated over-
night on a shaker at room temperature. The bacteria were spun in 
a chilled centrifuge for 10 min at 5000 rpm. Bacterial pellet was 
resuspended in 10 ml of BL21 lysis buffer (1× PBS, 1% Triton-100, 
1 mM DTT, 0.4% lysozyme, and protease inhibitor tablet), incu-
bated for 10 min, and sonicated twice for 30 s. The suspension was 
cleared at 13,000 rpm for 10 min. A 150-μl amount of 50% gluta-
thione-Sepharose beads (GE Healthcare, Little Chalfont, United 
Kingdom) was added to the supernatant, which was incubated for 
2 h with rotation at 4°C. Glutathione-Sepharose beads were 
washed three times with glutathione washing buffer (1× PBS, 1 mM 
DTT, and 0.1% Triton-X) and eluted for 30 min with glutathione 
elution buffer (100 mM Tris, pH 8, 150 mM NaCl, 20 mM glutathi-
one, and protease inhibitors). Alternatively, glutathione-Sepharose 
beads with GRHL2 protein attached were washed three times in 
PreScission cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM 
EDTA, 1 mM DTT, pH 7.0). The GST-GRHL2 on glutathione-Sepha-
rose beads was cleaved by adding 80 μl of PreScission Protease 
(GE Healthcare) per milliliter of PreScission cleavage buffer at 5°C 
overnight. The sample was spun at 2000 rpm, and the supernatant 
with the GST-cleaved GRHL2 was obtained. Proteins were dialyzed 
against p300 acetylation buffer overnight at 4°C using a 20,000 
MWCO Slide-A-Lyzer MINI Dialysis Unit (Thermo Scientific). Pro-
tein was analyzed on SDS–PAGE by Coomassie blue staining and 
quantified by comparison of Coomassie staining to a BSA stan-
dard and/or a bicinchoninic acid assay. Synthetic peptides were 
purchased from ThermoFisher Scientific with N-terminus acetyl 
group and C-terminus amidation: GRHL2 aa 420–442 (GAERKIRD-
EERKQNRKKGKGQAS) and scramble (IDEKNKGRERQRK)
Chromatin immunoprecipitation
For ChIP assay, HT1080 cell lines expressing empty vector/pMXS or 
GRHL2/pMXS cells were used and chromatin generated as described 
previously, with the following modifications (Kumar et al., 2011): 
1) Immunoprecipitation was performed with 3 μg of H3K27-Ac anti-
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